GLP-1for Fatty Liver Disease (NAFLD/NASH): 2026 Evidence &TreatmentGuide How semaglutide and tirzepatide treatNAFLDand NASH by reducing liver fat, inflammation, and fibrosis. Covers clinical trial results, monitoring, and who benefits most fromGLP-1therapy for liver health.
ShareGLP-1agonists are approved for thetreatmentof diabetes and for obesity. Why are patients with non-alcoholic fatty liver disease (NAFLD) suddenly being prescribedGLP-1agonists and what are the effects on the liver? To tackle these questions, let's start with some disease definitionsā¦ What isNAFLD?
Semaglutide is the firstGLP-1treatmentfor MASH and the second FDA-approved drug to treat fatty liver disease. The first drug, resmetirom (Rezdiffra, approved in spring 2024), works directly in ...
The FDA approved semaglutide (Wegovy) for thetreatmentof liver fibrosis due toNAFLD. Learn how semaglutide treats liver disease, who can take it, and more.
Background Based on the rapidly growing global burden of non-alcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), in order to evaluate the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in thetreatmentofNAFLDor NASH this paper presents a systematic review and meta-analysis of randomized controlled trials (RCTs).
In addition,GLP-1/glucose-dependent insulinotropic peptide (GIP)-1 dual agonists are a relatively new class of medications that have shown promise inNAFLDtreatment[18, 19]. However, further research is required to fully elucidate their mechanism of action and determine their long-term efficacy and safety.
